The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 11, 2020

Filed:

Jan. 23, 2017
Applicants:

Richard Brian Murphy, Jr., San Diego, CA (US);

Richard Brian Murphy, San Diego, CA (US);

Inventors:

Richard Brian Murphy, Jr., San Diego, CA (US);

Richard Brian Murphy, San Diego, CA (US);

Assignee:

Other;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 35/76 (2015.01); A61K 38/19 (2006.01); C07K 14/52 (2006.01); C12N 15/86 (2006.01); A61K 47/60 (2017.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
A61K 35/76 (2013.01); A61K 38/195 (2013.01); A61K 47/60 (2017.08); C07K 14/521 (2013.01); C07K 14/523 (2013.01); C12N 15/86 (2013.01); A61K 38/00 (2013.01); C12N 2795/00032 (2013.01); C12N 2795/00043 (2013.01);
Abstract

The present invention provides a recombinantly modified PEGylated bacteriophage expressing a mammalian antigen presenting cell chemoattractant. The present invention further provides methods of treatment of mammalian subjects having a bacterial infection by the administration of a pharmaceutically acceptable formulation of a recombinantly modified PEGylated bacteriophage expressing a mammalian antigen presenting cell chemoattractant. The present invention further provides pharmaceutically acceptable formulations of recombinantly modified PEGylated bacteriophage expressing a mammalian antigen presenting cell chemoattractant. The present invention further provides a method of inducing an antibacterial immune response in a mammalian subject having bacterial infection by the administration of a pharmaceutically acceptable formulation of a recombinantly modified PEGylated bacteriophage expressing a mammalian antigen presenting cell chemoattractant. The present invention further provides a recombinantly modified PEGylated bacteriophage that avoids neutralization by the Cas9 system. In one embodiment, the present invention further provides a recombinantly modified PEGylated bacteriophage expressing an anti-Cas9 protein. The present invention further provides a recombinantly modified PEGylated bacteriophage the genome of which has been modified to eliminate one or more protospacer adjacent motifs.


Find Patent Forward Citations

Loading…